October 13, 2016 / 12:37 PM / a year ago

BRIEF-Bluebird Bio provides update on Lentiglobin programs

Oct 13 (Reuters) - Bluebird Bio Inc

* Bluebird Bio provides update on Lentiglobin programs and research and development strategy at gene therapy day

* Bluebird Bio application for conditional approval for Lentiglobin in EU would be based on data from HGB-204 and HGB-205 studies of Lentiglobin

* Bluebird Bio application for conditional approval for Lentiglobin in EU would be also be based on available data from HGB-207, HGB-212 studies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below